Factors Associated with Poor Quality of Life in a Canadian Cohort of Patients with Inflammatory Bowel Disease: A Cross-sectional Study.
Crohn’s disease
Inflammatory bowel disease
Irritable bowel syndrome
Quality of life
Ulcerative colitis
Journal
Journal of the Canadian Association of Gastroenterology
ISSN: 2515-2092
Titre abrégé: J Can Assoc Gastroenterol
Pays: England
ID NLM: 101738684
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
26
08
2019
accepted:
05
04
2020
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
16
4
2021
Statut:
epublish
Résumé
Health-related quality of life (QoL) is often adversely affected in patients with inflammatory bowel disease (IBD). We aimed to identify factors associated with poor QoL among Canadian patients with IBD in clinical remission. We enrolled patients at a single academic tertiary care center with inactive IBD. All eligible patients completed a series of questionnaires that included questions on demographics, disease activity, anxiety, depression and the presence of irritable bowel syndrome (IBS) symptoms. Stool sample for fecal calprotectin (FC) was also collected to assess for subclinical inflammation. The primary outcome measure was QoL assessed by the short inflammatory bowel disease questionnaire (SIBDQ), with planned subgroup comparisons for fatigue, anxiety, depression and IBS symptoms. Ninety-three patients were eligible for inclusion in this study. The median SIBDQ scores were lower in patients with anxiety ( Anxiety, depression, fatigue and IBS symptoms are all independently associated with lower QoL in patients with inactive IBD. Clinicians are encouraged to screen for these important factors as they may detrimentally impact QoL in IBD patients even in clinical remission.
Sections du résumé
BACKGROUND
BACKGROUND
Health-related quality of life (QoL) is often adversely affected in patients with inflammatory bowel disease (IBD). We aimed to identify factors associated with poor QoL among Canadian patients with IBD in clinical remission.
METHODS
METHODS
We enrolled patients at a single academic tertiary care center with inactive IBD. All eligible patients completed a series of questionnaires that included questions on demographics, disease activity, anxiety, depression and the presence of irritable bowel syndrome (IBS) symptoms. Stool sample for fecal calprotectin (FC) was also collected to assess for subclinical inflammation. The primary outcome measure was QoL assessed by the short inflammatory bowel disease questionnaire (SIBDQ), with planned subgroup comparisons for fatigue, anxiety, depression and IBS symptoms.
RESULTS
RESULTS
Ninety-three patients were eligible for inclusion in this study. The median SIBDQ scores were lower in patients with anxiety (
CONCLUSIONS
CONCLUSIONS
Anxiety, depression, fatigue and IBS symptoms are all independently associated with lower QoL in patients with inactive IBD. Clinicians are encouraged to screen for these important factors as they may detrimentally impact QoL in IBD patients even in clinical remission.
Identifiants
pubmed: 33855267
doi: 10.1093/jcag/gwaa014
pii: gwaa014
pmc: PMC8023811
doi:
Types de publication
Journal Article
Langues
eng
Pagination
91-96Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.
Références
Gut. 2006 Jun;55(6):749-53
pubmed: 16698746
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S42-S48
pubmed: 31294384
J Crohns Colitis. 2010 Feb;4(1):7-27
pubmed: 21122488
Diabet Med. 2015 Jun;32(6):725-37
pubmed: 25440507
Inflamm Bowel Dis. 2018 Mar 19;24(4):742-751
pubmed: 29562277
Gut. 1998 Jul;43(1):29-32
pubmed: 9771402
Inflamm Bowel Dis. 2014 Aug;20(8):1407-15
pubmed: 24983982
Inflamm Bowel Dis. 2019 Jul 17;25(8):1399-1407
pubmed: 30689871
Aliment Pharmacol Ther. 2005 Mar 1;21(5):499-508
pubmed: 15740531
Inflamm Bowel Dis. 2012 Dec;18(12):2301-9
pubmed: 22359369
Inflamm Bowel Dis. 2018 Apr 23;24(5):966-976
pubmed: 29688466
Aliment Pharmacol Ther. 2011 Jan;33(1):106-14
pubmed: 21083587
Inflamm Bowel Dis. 2012 Aug;18(8):1540-9
pubmed: 21936030
Am J Gastroenterol. 2012 Mar;107(3):451-9
pubmed: 22085819
Dig Liver Dis. 2017 Dec;49(12):1314-1319
pubmed: 28882540
J Crohns Colitis. 2012 Dec;6(10):965-90
pubmed: 23040452
Inflamm Bowel Dis. 2005 Oct;11(10):909-18
pubmed: 16189421
Inflamm Bowel Dis. 2006 Jan;12(1):47-52
pubmed: 16374258
Cochrane Database Syst Rev. 2019 Apr 12;4:CD012680
pubmed: 30977111
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Chronic Dis Can. 2008;28(3):92-8
pubmed: 18341763
Health Technol Assess. 2013 Nov;17(55):xv-xix, 1-211
pubmed: 24286461
J Gastrointestin Liver Dis. 2006 Sep;15(3):237-41
pubmed: 17013448
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Am J Gastroenterol. 1996 Aug;91(8):1571-8
pubmed: 8759664
Inflamm Bowel Dis. 2006 Jan;12(1):38-46
pubmed: 16374257
Am J Gastroenterol. 2001 Oct;96(10):2921-8
pubmed: 11693327
J Health Psychol. 2016 Oct;21(10):2156-67
pubmed: 25805660
Lancet. 2007 Sep 8;370(9590):851-8
pubmed: 17826170
Frontline Gastroenterol. 2017 Jan;8(1):68-73
pubmed: 28839887
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):189-199
pubmed: 28404134
Aliment Pharmacol Ther. 2014 Apr;39(8):811-22
pubmed: 24612278
Am J Gastroenterol. 2002 Feb;97(2):389-96
pubmed: 11866278
Inflamm Bowel Dis. 2014 Jan;20(1):92-102
pubmed: 24193152
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Aliment Pharmacol Ther. 2016 Jul;44(1):3-15
pubmed: 27145394
Eur J Gastroenterol Hepatol. 2017 Sep;29(9):1086-1090
pubmed: 28639969
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Inflamm Bowel Dis. 2005 May;11(5):488-96
pubmed: 15867589